Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK PSO-4: Deucravacitinib in Japanese Psoriasis Patients
NCT03924427Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deucravacitinib in plaque psoriasis, psoriatic arthritis (PsA), erythrodermic psoriasis (EP) and 1 more, sponsored by Bristol Myers Squibb. Primary endpoints: Static Physician's Global Assessment 0/1 Response at 16 weeks and Psoriasis Area and Severity Index 75 Response at 16 weeks. Started Apr 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)erythrodermic psoriasis (EP)generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT03924427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924427.